MRC Centre for Neuropsychiatric Genetics and Genomics
Lead Research Organisation:
Cardiff University
Department Name: School of Medicine
Abstract
The main goal of the Centre is to understand how genes are involved in a range of common psychiatric and neurological disorders, and to use this knowledge to improve our understanding of how these diseases arise and to develop new approaches to diagnosis and treatment. We have known for a long time that genes play an important role in disorders such as schizophrenia, bipolar disorder, depression, attention deficit hyperactivity disorder (ADHD), Alzheimer disease and Parkinson disease. Now, using modern genetic technologies, we have begun to identify some of the specific genes involved. Centre scientists have been at the heart of these exciting developments, which have begun to yield novel insights into the brain mechanisms involved, and which have also raised important questions about the validity of current diagnostic approaches. For example our work has shown that intellectual disability, autism, ADHD and schizophrenia are likely to be much more closely related than previously believed. Our success with existing methods, together with the development of new approaches particularly the ability to determine the sequence of DNA (the genetic code) in large numbers of patients, means that we are confident that further work will allow us to identify more of the genes involved in these disorders and that this will deliver greater understanding into how these diseases arise and the relationships between them. Thus a major focus of ours over the next 5 years will be to continue our work aimed at identifying disease genes in these disorders and in understanding how genetic risk operates both across and within current diagnostic categories.
The second major focus of our work will be look at how risk genes lead to illness. This will be essential if we are to understand the mechanisms by which these diseases come about. This work will use a variety of approaches. First, we will look at the impact of risk genes in the general population for example on indexes of brain and cognitive development in the case of psychiatric disorders and on markers of inflammation, and cardiovascular health in the case of Alzheimer disease. This will help us understand how disease develops across the lifespan, and identify potentially modifiable risk factors or makers of those at increased risk of subsequent disease. The latter will be important for future studies aimed at early intervention. Second, we will develop animal and cellular models allowing us to study in detail the impact of risk genes on the function of nerve cells and brain circuits and on behaviour. Finally, we will study in human volunteers and patients how risk genes impact on brain structure and function using brain imaging methods. By studying cells, animals and patients we will be able to link abnormalities in brain function and behaviour seen in patients to abnormalities in cells and brain circuits. This will help us develop methods to stratify patient populations into specific groups for treatment studies as well to understand the mechanisms by which these diseases develop. These advances will be essential if we are to develop novel and more effective treatments for these disabling conditions.
The second major focus of our work will be look at how risk genes lead to illness. This will be essential if we are to understand the mechanisms by which these diseases come about. This work will use a variety of approaches. First, we will look at the impact of risk genes in the general population for example on indexes of brain and cognitive development in the case of psychiatric disorders and on markers of inflammation, and cardiovascular health in the case of Alzheimer disease. This will help us understand how disease develops across the lifespan, and identify potentially modifiable risk factors or makers of those at increased risk of subsequent disease. The latter will be important for future studies aimed at early intervention. Second, we will develop animal and cellular models allowing us to study in detail the impact of risk genes on the function of nerve cells and brain circuits and on behaviour. Finally, we will study in human volunteers and patients how risk genes impact on brain structure and function using brain imaging methods. By studying cells, animals and patients we will be able to link abnormalities in brain function and behaviour seen in patients to abnormalities in cells and brain circuits. This will help us develop methods to stratify patient populations into specific groups for treatment studies as well to understand the mechanisms by which these diseases develop. These advances will be essential if we are to develop novel and more effective treatments for these disabling conditions.
Technical Summary
We have established a Centre of Excellence in psychiatric genetics, focusing on psychiatric and neurodegenerative disorders such as schizophrenia, bipolar disorder, depression, ADHD, Alzheimer disease and Parkinson disease. Over the next 5 years we will retain a strong focus on gene discovery in order to deliver further important insights into disease pathogenesis. We will do this though our clinical, genetic and statistical expertise, our access to suitable patient cohorts, and our proven ability to participate in and provide leadership in large consortia. We will also continue to benefit from our structure of overlapping disease themes supported by a strong genomics, statistical and bioinformatics core. There will be an increasing focus on identifying rare mutations by NGS, and on understanding the significance of genetic findings for risk mechanisms, which will require integration with data from a variety of sources. Moreover, we are now well placed to use genetic findings to obtain greater understanding of pathogenic mechanisms, improve classification, identify biomarkers to aid prediction and intervention and identify novel treatment targets. Broadly speaking this work will take place in two settings. First we will explore the factors that mediate the effects of risk alleles on clinical phenotypes in longitudinal, population-based cohorts and identify biomarkers and modifiable markers of risk through integration of data from other risk factors, gene expression and epigenomics. Second, we will study the impact of risk alleles at molecular, cellular and systems levels through our imaging and cellular/animal models themes. Work in these areas will benefit from our access to patients carrying specific rare, high-penetrance mutations and has been greatly strengthened by our central participation in the Cardiff University Neuroscience and Mental Health Research Institute with which we will be co-located in the new Hadyn Ellis building.
Planned Impact
The main aim of the Centre is to understand how genes are involved in common psychiatric and neurological disorders, and to use this knowledge to improve our understanding of how these diseases arise and to develop new approaches to diagnosis and treatment. The personal and economic burden of these disorders is the largest of all categories of disorder and the development of more effective therapies is a pressing requirement for global health and wellbeing. There will thus be many beneficiaries of our work including sufferers, their families and the wider population upon which much of the economic burden falls. All of the Centre's programmes have specific non-academic impacts linked to their own communications plans. Here we focus on the most immediate areas of impact for the Centre as a whole.
Commercial and Private Sector
The identification of disease risk alleles is of profound interest to molecular, cellular and systems neuroscientists working in the pharmaceutical industry (e.g. Lilly, AZ, Janssen). This allows disease risk to be modeled in systems that are tractable to invasive measurement and intervention, which will be essential in order to identify disease mechanisms and novel drug targets. Those risk alleles that have been identified to date have been the focus of intense industry scrutiny and those emerging from our future work will attract the same level of interest. In addition the rat models we will develop and validate as part of the DEFINE programme will be made available to industry via our agreement with Sigma-Aldrich as will iPSC derived neurons from our patient cohorts via StemBANCC. Our validation of novel animal models of psychiatric disorders will benefit our partners Sigma-Aldrich. Our work on cognition and neuroimaging in relation to genetic risk factors will inform the development of new biomarkers for patient stratification in drug trails and for use as surrogate endpoints in experimental medicine and early phase clinical trials.
Public sector, policy and practice
Our genetics work and theorising has already spearheaded contemporary debate about psychiatric classification and diagnosis. Our future findings on the genetic overlaps and distinctions between current diagnostic groups will continue to inform this debate as psychiatry moves inexorably from the current descriptive system to one that is more in tune with underlying pathogenesis. Our work on genetic and other epidemiological risk markers will be relevant to early diagnosis and identification of those at risk of subsequent psychiatric and neurodevelopmental disorders. These studies will also allow hypothesis-driven studies of causal processes in the general population as well as in clinical samples and longitudinal and quasi-experimental designs. This will inform future intervention policies.
Wider public
Engagement with the general public and with patients and carers is an important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma and the research culture in the NHS in relation to Mental Health. Our commitment to this is based upon our belief that instead of regarding severe mental illnesses as essentially incurable conditions for which the therapeutic focus should be largely palliative, we should regard them as brain disorders which are increasingly tractable to research in genetics, neuroscience, epidemiology etc. We therefore aim to promote research into severe mental illness that focuses not only upon evaluating new models for delivering care but also on understanding pathogenesis and pathophysiology and developing new approaches to treatment.
Skills and Training
We train staff in genetics, statistics, bioinformatics, neuroscience, psychology and psychiatry. Their skills are applicable not only in academia but also more widely including in industry, the NHS, education and policy making.
Commercial and Private Sector
The identification of disease risk alleles is of profound interest to molecular, cellular and systems neuroscientists working in the pharmaceutical industry (e.g. Lilly, AZ, Janssen). This allows disease risk to be modeled in systems that are tractable to invasive measurement and intervention, which will be essential in order to identify disease mechanisms and novel drug targets. Those risk alleles that have been identified to date have been the focus of intense industry scrutiny and those emerging from our future work will attract the same level of interest. In addition the rat models we will develop and validate as part of the DEFINE programme will be made available to industry via our agreement with Sigma-Aldrich as will iPSC derived neurons from our patient cohorts via StemBANCC. Our validation of novel animal models of psychiatric disorders will benefit our partners Sigma-Aldrich. Our work on cognition and neuroimaging in relation to genetic risk factors will inform the development of new biomarkers for patient stratification in drug trails and for use as surrogate endpoints in experimental medicine and early phase clinical trials.
Public sector, policy and practice
Our genetics work and theorising has already spearheaded contemporary debate about psychiatric classification and diagnosis. Our future findings on the genetic overlaps and distinctions between current diagnostic groups will continue to inform this debate as psychiatry moves inexorably from the current descriptive system to one that is more in tune with underlying pathogenesis. Our work on genetic and other epidemiological risk markers will be relevant to early diagnosis and identification of those at risk of subsequent psychiatric and neurodevelopmental disorders. These studies will also allow hypothesis-driven studies of causal processes in the general population as well as in clinical samples and longitudinal and quasi-experimental designs. This will inform future intervention policies.
Wider public
Engagement with the general public and with patients and carers is an important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma and the research culture in the NHS in relation to Mental Health. Our commitment to this is based upon our belief that instead of regarding severe mental illnesses as essentially incurable conditions for which the therapeutic focus should be largely palliative, we should regard them as brain disorders which are increasingly tractable to research in genetics, neuroscience, epidemiology etc. We therefore aim to promote research into severe mental illness that focuses not only upon evaluating new models for delivering care but also on understanding pathogenesis and pathophysiology and developing new approaches to treatment.
Skills and Training
We train staff in genetics, statistics, bioinformatics, neuroscience, psychology and psychiatry. Their skills are applicable not only in academia but also more widely including in industry, the NHS, education and policy making.
Organisations
- Cardiff University, United Kingdom (Collaboration, Lead Research Organisation)
- Cardiff Metropolitan University, United Kingdom (Collaboration)
- University of Edinburgh, United Kingdom (Collaboration)
- Takeda Pharmaceutical Company (Collaboration)
- Institute of Zoology (Collaboration)
- University of Oviedo (Collaboration)
- The Jackson Laboratory (Collaboration)
- Foundation for Prader-Willi Research (FPWR) (Collaboration)
- Helmholtz Association of German Research Centres (Collaboration)
- University of Hamburg, Germany (Collaboration)
- Albert Ludwig University of Freiburg (Collaboration)
- University of Rome I (La Sapienza), Italy (Collaboration)
- University of Wuerzburg, Germany (Collaboration)
- University of Liverpool, United Kingdom (Collaboration)
- GW Pharmaceuticals (Collaboration)
- Social Research Unit at Dartington (Collaboration)
- Health and Care Research Wales (Collaboration)
- AstraZeneca plc (Collaboration)
- University of Pennsylvania, United States (Collaboration)
- Government of Wales (Collaboration)
- Boston University, United States (Collaboration)
- University of Nottingham (Collaboration)
- Saarland University, Germany (Collaboration)
- Psychiatric Genomics Consortium (PGC) (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- Washington University in St. Louis (Collaboration)
- MRC Harwell, United Kingdom (Collaboration)
- Medical University of Sofia (Collaboration)
- Oxford University Hospitals NHS Trust, United Kingdom (Collaboration)
- University of Bristol, United Kingdom (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Ludwig Maximilians University Munich (Collaboration)
- Renishaw Plc, United Kingdom (Collaboration)
- University of Glasgow, United Kingdom (Collaboration)
- FACE Recording & Measurement Systems Ltd (Collaboration)
- University of Exeter, United Kingdom (Collaboration)
- National Institutes of Health, United States (Collaboration)
- Washington University in St Louis, United States (Collaboration)
- EU-T0 (Collaboration)
- Mount Sinai Hospital (USA) (Collaboration)
- CHDI Foundation (Collaboration)
- University of Sussex, United Kingdom (Collaboration)
- Central Inst of Mental Health Mannheim (Collaboration)
- Wellcome Trust, LONDON (Collaboration)
- University of Cantabria, Spain (Collaboration)
- Lancaster University (Collaboration)
- Goethe University of Frankfurt am Main, Germany (Collaboration)
- Fondazione Santa Lucia (Collaboration)
- King's College London, United Kingdom (Collaboration)
- Genetic and Environmental Risk in Alzheimer's Disease (GERAD) (Collaboration)
- Leyden Delta BV (Collaboration)
- University of Southampton, United Kingdom (Collaboration)
- Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium (Collaboration)
- University College London, United Kingdom (Collaboration)
- Friedrich-Alexander University (Collaboration)
- University of Navarra, Spain (Collaboration)
- Eisai Ltd (Collaboration)
- University of Bath, Bath (Collaboration)
- International Multicentre persistent ADHD CollaboraTion (IMpACT) (Collaboration)
- University of Duisburg-Essen, Germany (Collaboration)
- University of Bonn, Germany (Collaboration)
- Bangor University, United Kingdom (Collaboration)
- German Centre for Neurodegenerative Diseases (Collaboration)
- Psychiatric GWAS Consortium (PGC) (Collaboration)
- BLISS (Collaboration)
- Mayo Foundation for Medical Education and Research (MFMER) (Collaboration)
- Royal College of Surgeons in Ireland, Ireland (Collaboration)
- Genomics England (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Massachusetts General Hospital (Collaboration)
- University of Oregon, United States (Collaboration)
- Asterand (Collaboration)
- Brigham Young University (Collaboration)
- Eisai Inc (Collaboration)
- Italian Institute of Technology (Istituto Italiano di Tecnologia IIT) (Collaboration)
- National Institute for Health Research, United Kingdom (Collaboration)
- Free University of Berlin, Germany (Collaboration)
- Karolinska Institute, Sweden (Collaboration)
- University of California, San Francisco, United States (Collaboration)
- Neuroscience; IOP (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- University of Lille (Collaboration)
- Queen's University of Belfast, United Kingdom (Collaboration)
- Grants Admin Office (Collaboration)
- University of Cambridge, United Kingdom (Collaboration)
- JPND Research (Collaboration)
- Broad Institute (Collaboration)
- Medical Research Council (Collaboration)
- Autonomous University of Madrid, Spain (Collaboration)
- Hospital de Sant Pau (Collaboration)
- National Center for Biotechnology Information (NCBI) (Collaboration)
- Swansea University, United Kingdom (Collaboration)
- University of Sao Paolo (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
- University of Dublin (Collaboration)
People |
ORCID iD |
| Michael John Owen (Principal Investigator) |
Publications
Absoud M
(2017)
A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).
in Health technology assessment (Winchester, England)
Abu-Akel A
(2017)
Autistic and schizotypal traits and global functioning in bipolar I disorder.
in Journal of affective disorders
Adam M
(2017)
EHMT1/GLP; Biochemical Function and Association with Brain Disorders
in Epigenomes
Addicoat A
(2020)
Adult mood problems in children with neurodevelopmental problems: evidence from a prospective birth cohort followed to age 50.
in Social psychiatry and psychiatric epidemiology
Agha SS
(2017)
Parent Psychopathology and Neurocognitive Functioning in Children With ADHD.
in Journal of attention disorders
Agha SS
(2017)
Maternal psychopathology and offspring clinical outcome: a four-year follow-up of boys with ADHD.
in European child & adolescent psychiatry
Aguirregomozcorta M
(2014)
Pregnancy and drug use in neurological disease.
in Journal of neurology
Ahmad S
(2018)
Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Airdrie JN
(2018)
Facial Emotion Recognition and Eye Gaze in Attention-Deficit/Hyperactivity Disorder With and Without Comorbid Conduct Disorder.
in Journal of the American Academy of Child and Adolescent Psychiatry
| Description | Appointed member of National Institute for Health Research Development of a Ten Year Strategy for Mental Health - Children and Young People |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://www.gov.uk/government/publications/a-framework-for-mental-health-research |
| Description | Biomarkers in HD Group |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://www.ninds.nih.gov/Disorders/All-Disorders/Huntingtons-Disease-Information-Page |
| Description | Deputy Director DPUK |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Description | Development of the world's first interactive programme to help sufferers of bipolar disorder better manage their conditions |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | This has allowed those who suffer with bipolar disorder to better manager their conditions. |
| Description | Early Intervention for Psychosis in Wales |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Impact | I sit on the Welsh Early Intervention in Psychosis steering and advisory group. This is led by Public Health Wales and oversees a commitment of £1M from Welsh government which has been committed in recent years following consultation and lobbying by the national group on which I am the psychiatric lead. |
| Description | European Huntington's Disease Network (EHDN) |
| Geographic Reach | Europe |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Aims to improve the quality of life and treatment available to HD patients and their families. Has working groups producing guidelines on specific issues in HD. Has updated genetic counselling and quality of life guidelines in HD in the past. Current initiatives include consideration and production of new guidelines for driving in HD, dysphagia in HD, reporting of incidental findings in HD. |
| URL | http://www.ehdn.org/ |
| Description | FPWR Pre-Clinical Animal Network |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a advisory committee |
| URL | http://research.fpwr.org/blog/de-risking-pws-drug-development-through-preclinical-screening |
| Description | Founded and chair Campaign Working Group for Maternal Mental Health Alliance |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Impact | Through Comic Relief Funded campaign "Everyone's Business" - have influenced provision of Perinatal Mental Health Services in UK. With 375 million pounds of new funding being committed to the development of new specialist services. |
| URL | http://everyonesbusiness.org.uk |
| Description | Huntington Society of Canada Research Board |
| Geographic Reach | North America |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://www.huntingtonsociety.ca/ |
| Description | MQ Funding Priority Setting Meeting on Adolescent Mental Health |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | MRC Expert Group Discussion on Child and Adolescent Mental Health |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | Member FRIMEDBIO Panel 7 (Neuroscience) Research Council of Norway |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://www.forskningsradet.no/en/Funding/FRIMEDBIO/1208964208385 |
| Description | Member of Welsh Assembly Government and CAMHS Together for Children and Young People Expert Reference Group |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Description | Member of the BAP guidelines group on Bipolar Disorder |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Member of the Executive Committee on ECT at the RCPsych |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | I am promoting the use of ECT and the use of maintenance ECT in the UK. This has already resulted in better acceptance of these treatments. |
| Description | Membership of ARUK grant review board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | Paper (2016) Thapar A, Cooper M, Rutter M, Neurodevelopmental Disorders: a personal view, The Lancet Psychiatry [Epub ahead of print] |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Paper in Child Psychology Psychiatry entitled "What have we learnt about the causes of ADHD?" |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Paper in The Lancet entitled "Attention Deficit Hyperactivity Disorder" [In Press] 2016 |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Speaking at V Annual Meeting on Therapeutics in Psychiatry, Barcelona, 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Speaking at the Together for Children and Young People Conference, Cardiff, 22 June 2015 |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Wellcome Trust Biomedical Resources and Technology Development Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| URL | https://wellcome.ac.uk/ |
| Description | Work on the penetrance of CNVs |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | 1/3 genetic analysis of the international cohort collection for bipolar disorder |
| Amount | £101,154 (GBP) |
| Funding ID | MH106531-02 |
| Organisation | National Institute of Mental Health |
| Sector | Hospitals |
| Country | Sri Lanka |
| Start | 04/2015 |
| End | 01/2018 |
| Description | 5/7 Psychiatric genomics consortium: Finding actionable variation |
| Amount | £905,712 (GBP) |
| Funding ID | MH109514-01 |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Mental Health (NIMH) |
| Sector | Public |
| Country | United States |
| Start | 06/2016 |
| End | 03/2018 |
| Description | 7/9 rare genetics disorders as a window into the genetic architecture of mental disorders |
| Amount | £220,883 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 08/2019 |
| End | 03/2024 |
| Description | A detailed clinical-radiological correlation of disability in Multiple Sclerosis |
| Amount | £34,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 07/2016 |
| Description | A device for delivering stem cell therapies to the human brain |
| Amount | £74,812 (GBP) |
| Organisation | European Social Fund (Welsh Government/ EU) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 03/2018 |
| Description | A genetic study of the implications of gender in ADHD and other neurodevelopmental disorders |
| Amount | £250,000 (GBP) |
| Funding ID | 106047/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 01/2019 |
| Description | A genomic medicine approach to identifying novel drug targets for Parkinson's disease |
| Amount | £45,903 (GBP) |
| Funding ID | Co-applicant |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 07/2018 |
| Description | A genomic medicine approach to identifying novel drug targets for dementia |
| Amount | £45,904 (GBP) |
| Funding ID | ARUK-PPG2017A-10 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 10/2018 |
| Description | A high content analysis platform for analysing dementia-associated genetic variation |
| Amount | £108,300 (GBP) |
| Funding ID | ARUK-EG2017A-1 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 09/2017 |
| Description | A long term follow up study for MS patients who have completed the alumtuzumab extension study |
| Amount | £7,467 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 05/2020 |
| Description | A multi-center, open-label study evaluating the safety, tolerability and efficacy of pridopidine in patients with Huntington's disease (open PRIDE-HD) |
| Amount | £3,485 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 01/2018 |
| Description | A multi-site, prospective, longitudinal, cohort study measuring cerebrospinal fluid-mutant Huntington protein in patients with Huntington's disease |
| Amount | £45,500 (GBP) |
| Organisation | F. Hoffmann-La Roche AG |
| Sector | Private |
| Country | Global |
| Start | 01/2019 |
| End | 02/2021 |
| Description | A phase 2, dose escalating randomised parallel group double blind controlled study evaluating the safety and efficacy of pridopidine twice daily versus placebo for symptomatic treatment in patients with Huntington's disease |
| Amount | £70,220 (GBP) |
| Organisation | TEVA Pharmaceuticals |
| Sector | Private |
| Country | Israel |
| Start | 11/2014 |
| End | 11/2016 |
| Description | A phase 2, randomised, placebo-controlled, double blind, proof of concept study of the efficacy and safety of PF-02545920 in subjects with Huntington's Disease |
| Amount | £7,711 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 12/2017 |
| Description | A prospective multicentre observational post authorisation safety to evaluate the long term safety profile of lemtrada treatment in patients with relapsing forms of MS |
| Amount | £3,910 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2015 |
| End | 10/2020 |
| Description | A prospective, observational study to evaluate quality of life, patient reported outcomes, and safety in patients with relapsing-remitting Multiple Sclerosis who are being treated with Alemtuzumab (Lemtrada) in routine clinical practice |
| Amount | £1,456 (GBP) |
| Organisation | Sanofi |
| Sector | Private |
| Country | Global |
| Start | 12/2016 |
| End | 12/2019 |
| Description | A randomised, double blind placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of intrathecally administered ISIS 443139 in patients with early manifest Huntingtons disease |
| Amount | £99,991 (GBP) |
| Organisation | Ionis Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 01/2017 |
| End | 12/2019 |
| Description | A randomized multicentre, double-blind placebo-controlled phase III clinical study to evaluate the efficacy and safety of intrathecally administered R07234292 (RG6042) in patients with manifest Huntington's disease |
| Amount | £64,701 (GBP) |
| Organisation | Roche Pharmaceuticals |
| Sector | Private |
| Country | Global |
| Start | 01/2019 |
| End | 05/2022 |
| Description | A study of prognostic and disease related biomarkers in MS and related disorders |
| Amount | £103,508 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 06/2018 |
| Description | ARUK Wales Network Centre |
| Amount | £40,000 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2018 |
| Description | Adolescent Data Platform - Co-Applicant |
| Amount | £799,963 (GBP) |
| Funding ID | MQBF/3 |
| Organisation | MQ Transforming Mental Health |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2020 |
| Description | Adult outcomes of childhood neurodevelopment problems |
| Amount | £20,494 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 06/2016 |
| Description | Advanced pharmacological characterisation of a novel neuroprotective and cognitive enhancer drug for the treatment of neurodegenerative disorders |
| Amount | £49,423 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 04/2019 |
| Description | Alzheimer's Research UK Wales Network Centre |
| Amount | £40,000 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2017 |
| Description | An observational study of neurocognitive function in patients undergoing stereotactic radiosurgery at Velindre Cancer Centre |
| Amount | £75,000 (GBP) |
| Funding ID | Co-applicant |
| Organisation | Velindre NHS Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 02/2019 |
| Description | An open label extension study to investigate the long term safety, tolerability and efficacy of PF-02545920 in subjects with Huntington's disease who previously completed study A8241021 |
| Amount | £33,761 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 12/2017 |
| Description | An open-label extension study to evaluate the long-term safety and tolerability of intrathecally administered R07234292 (RG6042) in patients with Huntington's disease (BN40955) |
| Amount | £58,776 (GBP) |
| Organisation | Roche Pharmaceuticals |
| Sector | Private |
| Country | Global |
| Start | 10/2019 |
| End | 03/2023 |
| Description | An open-label extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 443139 in Huntington's Disease patients who participated in prior investigational studies of ISIS 443139 |
| Amount | £57,291 (GBP) |
| Organisation | Ionis Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 04/2018 |
| End | 10/2019 |
| Description | Are Sleep Difficulties in ADHD an index of neurodevelopmental severity? - Co-Applicant |
| Amount | £57,539 (GBP) |
| Organisation | The Waterloo Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 07/2019 |
| Description | Are astrocytes required for optimal survival and function of dopaminergic implants |
| Amount | £19,812 (GBP) |
| Funding ID | G-1105 |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 06/2016 |
| Description | Attention Deficit Hyperactivity Disorder |
| Amount | £250,000 (GBP) |
| Funding ID | Maria Niarchou |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 05/2020 |
| Description | Automated assessment of timing and movement signatures in Huntington's disease |
| Amount | £41,672 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2016 |
| Description | Biological dissection of phenotypic heterogeneity in HD |
| Amount | £100,000 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 03/2022 |
| Description | Biomarkers in pain in Parkinson's disease |
| Amount | £5,000 (GBP) |
| Funding ID | K-1301 |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 08/2017 |
| Description | Bipolar Education Programme (BEPC) |
| Amount | £5,000 (GBP) |
| Organisation | Baily Thomas Charitable Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2016 |
| End | 10/2017 |
| Description | Brain Repair and Intracranial Neurotherapeutics - the Wales BRAIN Unit |
| Amount | £800,000 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | Brain Repair and Intracranial Neurotherapeutics - the Wales BRAIN Unit |
| Amount | £1,200,000 (GBP) |
| Organisation | Health and Care Research Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2018 |
| Description | Cardiff Fetal Tissue Bank |
| Amount | £202,304 (GBP) |
| Funding ID | MR/M02475X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 03/2018 |
| Description | Cardiff Translational Drug Discovery Centre (CTDDC) |
| Amount | £2,312,749 (GBP) |
| Funding ID | Co-applicant |
| Organisation | Government of Wales |
| Department | Welsh European Funding Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2022 |
| Description | Cell-specific gene regulation in the developing human brain and genetic risk for neuropsychiatric disorders |
| Amount | £553,942 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 04/2022 |
| Description | Cell-specific gene regulation in the developing human brain and genetic risk for neuropsychiatric disorders |
| Amount | £553,942 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 04/2022 |
| Description | Centre for Ageing and Dementia Research (CADR) |
| Amount | £386,341 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | Centre for Ageing and Dementia Research (CADR) |
| Amount | £1,200,000 (GBP) |
| Funding ID | 507827 |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2018 |
| Description | Characterisation of a cortical FoxP1 |
| Amount | £1,500 (GBP) |
| Funding ID | 202632/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 08/2016 |
| Description | Characterisation of the natural history of HD and assessment of feasibility of HD clinical research within the network of HD clinical centres |
| Amount | £1,151,043 (GBP) |
| Organisation | University Hospital Ulm |
| Sector | Hospitals |
| Country | Germany |
| Start | 01/2016 |
| End | 12/2018 |
| Description | Characterising the dynamics of repeat expansion in Huntington's disease |
| Amount | £85,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | Characterising the effects of genetic modifiers of Huntington's disease in the R6/1 HD mouse model |
| Amount | £199,788 (GBP) |
| Funding ID | 109087/Z/15/A |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | Comorbidity and synapse biology in clinically overlapping psychiatric disorders (COSYN) |
| Amount | € 224,500 (EUR) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 01/2016 |
| End | 12/2020 |
| Description | Comorbidity and synapse biology in clinically overlapping psychiatric disorders (COSYN) |
| Amount | € 224,500 (EUR) |
| Funding ID | 667301 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2016 |
| End | 12/2020 |
| Description | DGKH: A key link connecting fatty acid metabolism, stress and bipolar disorder |
| Amount | £128,638 (GBP) |
| Organisation | The Waterloo Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 05/2019 |
| Description | DNA repair in Huntington's disease and other repeat-associated disorders |
| Amount | £150,321 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | DRI Costs |
| Amount | £1,123,799 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2022 |
| Description | Deconvoluting the dementia phenotype using functional genomics and computational approaches |
| Amount | £537,913 (GBP) |
| Organisation | Government of Wales |
| Department | Welsh European Funding Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 10/2022 |
| Description | Dementia Research Institute - Cardiff Centre |
| Amount | £4,658,000 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 08/2022 |
| Description | Dementia Research Institute - Equipment and Capital Award |
| Amount | £4,500,000 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2020 |
| Description | Dementia Research Institute - High Content Imaging Systems |
| Amount | £600,000 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2022 |
| Description | Dementia Research Institute - Studentship |
| Amount | £892,000 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2022 |
| Description | Dementias Platform UK |
| Amount | £1,235,048 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 06/2019 |
| Description | Detecting simple repeat sequences in the genome and their effects in dementias |
| Amount | £48,508 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2019 |
| Description | Determining mortality statistics for Multiple Sclerosis from South Wales registry |
| Amount | £61,368 (GBP) |
| Organisation | Novartis |
| Sector | Private |
| Country | Global |
| Start | 03/2015 |
| End | 12/2018 |
| Description | Determining the epidemiology of Multiple Sclerosis |
| Amount | £348,511 (GBP) |
| Organisation | Novartis |
| Sector | Private |
| Country | Global |
| Start | 09/2016 |
| End | 09/2019 |
| Description | Determining the mechanisms of striatal dysfunction in SGCE mutation positive myoclonus dystonia using an iPSC-derived neuronal cell model |
| Amount | £717,566 (GBP) |
| Funding ID | MR/P008593/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2021 |
| Description | Developing a cognitive assessment tool for use in NHS psychiatric services |
| Amount | £47,080 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2019 |
| Description | Developing a short animation on what it means to have ADHD |
| Amount | £4,988 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 06/2019 |
| Description | Developing clinical applications for a novel multi-task functional assessment |
| Amount | £49,902 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2017 |
| Description | Developing glioma organ dot cultures |
| Amount | £90,000 (GBP) |
| Funding ID | NC/N002423/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | Developing stem cell technologies for the neurodegeneration of Alzheimer's disease: Assessing the capacity of embryonic stem cell-derived projection neurons and interneurons to integrate in adult cortex |
| Amount | £150,000 (GBP) |
| Organisation | Campaign for Alzheimer's Research in Europe |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 09/2019 |
| Description | Development of head fixed behavioural paradigms to probe neural activity in neurological disease models in the awake brain |
| Amount | £33,833 (GBP) |
| Funding ID | Adam Ranson |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 12/2016 |
| Description | Dynamically networked brain - DyNet-BRAIN: A statistical machine learning approach to dynamic brain connectivity analysis for the extraction of dynamic and multimodal connectomic biomarkers for the diagnosis of psychiatric disorders |
| Amount | £86,904 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2016 |
| End | 12/2019 |
| Description | Early-onset depression: Characterising development and identifying risks |
| Amount | £763,680 (GBP) |
| Funding ID | MR/R004609/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 11/2020 |
| Description | Effect of APOE genotype on synaptic function in late onset Alzheimer's disease (LOAD) |
| Amount | £59,860 (GBP) |
| Funding ID | ARUK-CRF2016A-1 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 02/2019 |
| Description | Ensuring quality maternal care in adverse environment |
| Amount | £505,203 (GBP) |
| Funding ID | BB/P002307/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 12/2019 |
| Description | Establishing post-GWAS pharmaco-MRI: A Multimodal neuroimaging assessment of the molecules and confer genetic risk for psychiatric and neurodegenerative disorders |
| Amount | £85,213 (GBP) |
| Funding ID | Thomas Lancaster |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 03/2019 |
| Description | Establishing the relationship between anti-microbial host defence and the initiation of tissue fibrosis in peritoneal dialysis |
| Amount | £198,821 (GBP) |
| Funding ID | RP_024_20160304 |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | European prevention of Alzheimer's dementia consortium |
| Amount | £104,414 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2015 |
| End | 12/2019 |
| Description | Examining the effects of four phytocannabinoids (CBD, CBDV, DBDA, THCV (chronic dosing, at a range of doses) on PWS-IC behaviour in a number of tasks |
| Amount | £81,919 (GBP) |
| Funding ID | 20150827 |
| Organisation | GW Pharmaceuticals |
| Sector | Private |
| Country | United Kingdom |
| Start | 07/2015 |
| End | 03/2018 |
| Description | Expanding DPUK genetics and integrating with inflammation/immunity research |
| Amount | £100,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2019 |
| Description | Exploring cognitive training as a non-pharmaceutical intervention for people with Huntington's disease |
| Amount | £94,714 (GBP) |
| Organisation | Gossweiler Foundation |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 05/2016 |
| End | 09/2017 |
| Description | Exposing the link between placental endocrine dysfunction and offspring behavioural outcomes |
| Amount | £551,834 (GBP) |
| Funding ID | BB/P008623/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | Feasibility Study of a Neurodevelopmental Research Assessment Centre |
| Amount | £287,278 (GBP) |
| Funding ID | 267-2825 |
| Organisation | The Waterloo Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | Feasibility of a walking programme for people with Huntington's disease within a city environment |
| Amount | £9,240 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 12/2016 |
| Description | Feasibility of large-scale, international, clinical-genetic study of postpartum psychosis |
| Amount | £89,126 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 11/2021 |
| Description | Fetal derived iPS cells as a source of donor cells for a regeneration medicine approach to treating Huntington's disease |
| Amount | £36,875 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 03/2017 |
| Description | Flexible Funding |
| Amount | £625,000 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 03/2023 |
| Description | Further development and feasibility trial of an online psychoeducational intervention for adolescent depression |
| Amount | £740,642 (GBP) |
| Funding ID | NIHR-FS-PD-2018 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Future Minds Programme |
| Amount | £650,000 (GBP) |
| Organisation | The Waterloo Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2024 |
| Description | GW4 Biomed DTP - Optimizing adult mental health outcomes in children with neuordevelopmental problems |
| Amount | £75,457 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 04/2023 |
| Description | Gene expression regulation in CD4+ T cell dysfunction in multiple sclerosis |
| Amount | £39,798 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2018 |
| Description | Gene regulatory variation in the developing human brain and its role in neuropsychiatric disorders |
| Amount | £245,707 (GBP) |
| Funding ID | MR/L010674/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 12/2017 |
| Description | Generating cells for cell replacement therapy in Huntington's: Is FoxP1 important for the production of striatal donor cells |
| Amount | £10,000 (GBP) |
| Funding ID | M423-F1 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 03/2017 |
| Description | Generation of a human iPSC model of X-linked frontotemporal dementia: modelling proteostasis network dysfunction in dementia |
| Amount | £78,948 (GBP) |
| Funding ID | Co-applicant |
| Organisation | BRACE (Alzheimer's disease charity) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 07/2018 |
| Description | How CTIP2 deficiency drives medium spiny neuron degeneration and dysfunction: implications in Huntington's disease pathogenesis |
| Amount | £708,068 (GBP) |
| Funding ID | MR/R022429/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2021 |
| Description | How do cytokines signalling via STAT1 and STAT3 determine the course of synovial inflammation |
| Amount | £898,336 (GBP) |
| Funding ID | 20770 |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2015 |
| End | 11/2020 |
| Description | Human Brain Project |
| Amount | £152,154 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 04/2016 |
| End | 03/2018 |
| Description | IDEA - Integrated DEmentiA research enviornment |
| Amount | £1,882,982 (GBP) |
| Funding ID | MR/M009076/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2016 |
| Description | IMPC: Characterisation a novel Alzheimer's disease susceptibility locus |
| Amount | £24,317 (GBP) |
| Funding ID | MR/P024939/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 11/2018 |
| Description | INTENSE - Integrated neurotoxicity testing for electrophysiological and neurocellular and seizurogenic effects |
| Amount | £21,861 (GBP) |
| Funding ID | NC/C014101/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 06/2015 |
| Description | Identification and characterisation of genetic variation that modifies age at onset in Huntington's disease |
| Amount | £82,000 (GBP) |
| Organisation | Cardiff University |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | Identification of coding variants in DNA repair genes affecting age at onset of Huntington's disease |
| Amount | £18,911 (GBP) |
| Organisation | European Huntington's Disease Network (Euro-HD) |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 08/2016 |
| End | 07/2017 |
| Description | Identification of genetic modifiers in Huntington's disease |
| Amount | £132,459 (GBP) |
| Funding ID | A-10482 |
| Organisation | CHDI Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 03/2016 |
| End | 02/2018 |
| Description | Identify new potential cellular targets (pathways, molecules, genes) for therapeutic intervention in schizophrenia |
| Amount | £1,021,691 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Identify new potential cellular targets (pathways, molecules, genes) for therapeutic intervention in schizophrenia |
| Amount | £1,021,691 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Identify new potential cellular targets (pathways, molecules, genes) for therapeutic intervention in schizophrenia |
| Amount | £1,021,691 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Identifying clinical and cognitive endophenotypes for bipolar disorder: Genetic risk score analysis of tow large poplulation charts |
| Amount | £73,207 (GBP) |
| Organisation | Mental Health Research UK (MHRUK) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2019 |
| Description | Identifying genetic biomarkers of survival for bowel cancer to aid patient management |
| Amount | £90,000 (GBP) |
| Organisation | Tenovus |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2022 |
| Description | Identifying the contribution of mental disorder risk alleles to childhood neurodevelopment |
| Amount | £237,940 (GBP) |
| Funding ID | MR/M012964/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 08/2017 |
| Description | Identifying the pathogenic triggers of CD8 T cells in multiple sclerosis |
| Amount | £173,892 (GBP) |
| Funding ID | 105753/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 08/2017 |
| Description | Image Clarity for a multi-site collection of MRI data aimed at linking brain imaging markers with biofluid markers (Protocol and Imaging Manual drafting and review) |
| Amount | £20,329 (GBP) |
| Organisation | CHDI Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 07/2019 |
| End | 04/2022 |
| Description | Imaging immunity in the genetic risk for Alzheimer's disease |
| Amount | £191,580 (GBP) |
| Organisation | Government of Wales |
| Department | Welsh European Funding Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | In vivo imaging of Tau distribution in the brain |
| Amount | £44,743 (GBP) |
| Organisation | Welsh Local Government Association |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 03/2017 |
| Description | Individualising the risk of recurrence for women with bipolar disorder in the perinatal period |
| Amount | £275,769 (GBP) |
| Funding ID | MR/R017557/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 08/2021 |
| Description | Integrated Neuroscience Programme |
| Amount | £772,390 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2020 |
| Description | Integrated Neuroscience Programme |
| Amount | £865,074 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2019 |
| Description | Integrating genetic and functional data to identify pathogenic pathways modifying the progression and phenotypic expression of Huntington's disease |
| Amount | £353,485 (GBP) |
| Organisation | CHDI Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 05/2019 |
| End | 04/2021 |
| Description | Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health. |
| Amount | £971,676 (GBP) |
| Funding ID | MC_PC_17212 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health. |
| Amount | £971,676 (GBP) |
| Funding ID | MC_PC_17212 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health. |
| Amount | £971,676 (GBP) |
| Funding ID | MC_PC_17212 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | Intellectual disability and mental health: Assessing genomic impact on neurodevelopment (IMAGINE) |
| Amount | £850,450 (GBP) |
| Funding ID | MR/N022572/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 07/2019 |
| Description | Investigating PLCG2 and P522R variant PLCG2 in human IPSC models of dementia |
| Amount | £275,000 (GBP) |
| Organisation | Eisai Inc |
| Sector | Private |
| Country | United States |
| Start | 06/2018 |
| End | 05/2020 |
| Description | Investigating a placental origin for pregnancy and postpartum mood disorders |
| Amount | £719,568 (GBP) |
| Funding ID | MR/M013960/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 05/2018 |
| Description | Investigating alternative immunosuppression regimes to promote survival of human esc-derived dopaminergic grafts for Parkinson's disease |
| Amount | £2,000 (GBP) |
| Organisation | Lister Institute of Preventive Medicine |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 07/2016 |
| Description | Investigating genetic and environmental risk for psychosis mediated through L-Type voltage gated calcium channels |
| Amount | £764,295 (GBP) |
| Funding ID | MR/R011397/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 10/2021 |
| Description | Investigating resilience to schizophrenia in those at genetic risk |
| Amount | £75,040 (GBP) |
| Organisation | Brain & Behaviour Research Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2017 |
| End | 09/2019 |
| Description | Investigating sex differences in risk for common mental health problems |
| Amount | £103,347 (GBP) |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 02/2021 |
| Description | Investigating the association between large rare genetic copy number variants and physical illness in schizophrenia |
| Amount | £30,811 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 12/2016 |
| Description | Investigating the brain role of Setd1a in relation to schizophrenia and developmental disorders |
| Amount | £18,012 (GBP) |
| Funding ID | MR/P026176/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 03/2018 |
| Description | Investigating the early outcomes of child ADHD: Establishing a Wales-wide sample - Co-Investigator |
| Amount | £47,712 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 01/2018 |
| Description | Investigating the potential of the sphingosine-1-phosphate receptor 1 modulators for the treatment of psychiatric disorders |
| Amount | £47,621 (GBP) |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 03/2017 |
| Description | Investigating the role of gene expression regulation in pathological CD4+ T-cell function in multiple sclerosis |
| Amount | £150,518 (GBP) |
| Organisation | Guarantors of Brain |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 07/2019 |
| Description | Investigating the significance of novel splice variants of the Htt gene in Huntington's disease |
| Amount | £39,900 (GBP) |
| Funding ID | Alis Hughes |
| Organisation | European Huntington's Disease Network (Euro-HD) |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 01/2015 |
| End | 07/2016 |
| Description | Investigating the therapeutic potential of manipulating DNA repair in Huntington's disease |
| Amount | £31,184 (GBP) |
| Organisation | European Huntington's Disease Network (Euro-HD) |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 02/2016 |
| End | 01/2017 |
| Description | Is a lack of glucose the cause of graft death? Towards the first glucose releasing biomaterials for cell therapies |
| Amount | £18,868 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 07/2019 |
| Description | Is interneuron transplantation feasible in temporal lobe epilepsy |
| Amount | £30,000 (GBP) |
| Funding ID | PGE1601 |
| Organisation | Epilepsy Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 05/2018 |
| Description | Japan Partnering Award: The generation of eye tissues from human induced pluripotent stem (iPS) cells |
| Amount | £47,959 (GBP) |
| Funding ID | BB/R021244/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2022 |
| Description | Large scale linkage of genetic and health informatics data in schizophrenia to investigate the impact of copy number variants on physical health |
| Amount | £50,000 (GBP) |
| Funding ID | MQDS16/36 |
| Organisation | MQ Transforming Mental Health |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 09/2020 |
| Description | Life-style, exercise and activity package for people living with progressive Multiple Sclerosis |
| Amount | £293,296 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | Lifestyle targets for improving prognosis in Huntington's disease (DOMINO-HD) |
| Amount | £154,673 (GBP) |
| Organisation | Gossweiler Foundation |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 04/2019 |
| End | 03/2023 |
| Description | MRC Centre for Neuropsychiatric Genetics and Genomics |
| Amount | £15,000 (GBP) |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2019 |
| Description | Making the invisible visible: Using lived experiences of severe mental illness around childbirth to co-produce tools for individualised pregnancy planning |
| Amount | £66,000 (GBP) |
| Funding ID | HS-18-33(T) |
| Organisation | Health and Care Research Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2021 |
| Description | MassArray System: Nucleic Acid detection and Quantification Platform |
| Amount | £115,517 (GBP) |
| Funding ID | SCCEG-05 |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2016 |
| Description | Miniature microscope to image neuronal ensembles in rodent models of neuropsychiatric disorders |
| Amount | £210,000 (GBP) |
| Organisation | Welsh Local Government Association |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2016 |
| Description | Molecular Genetic Studies of Schizophrenia |
| Amount | £2,407,099 (GBP) |
| Funding ID | MR/P005748/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 11/2021 |
| Description | Multi-Domain lifestyle targets for improving prognosis in Huntington's disease (DOMINO-HD) |
| Amount | £254,588 (GBP) |
| Organisation | Alzheimer’s Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2022 |
| Description | Multi-centre, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of poesimod to teriflunomide to teriflunomid in subjects with relapsing multiple sclerosis |
| Amount | £26,089 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 12/2016 |
| Description | Multi-scale and multi-modal assessment of coupling in the healthy and diseased brain |
| Amount | £4,953,467 (GBP) |
| Funding ID | 104943/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 06/2021 |
| Description | National Centre for Mental Health |
| Amount | £3,000,000 (GBP) |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2018 |
| Description | National Centre for Mental Health |
| Amount | £2,000,000 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | National Centre for Mental Health |
| Amount | £2,000,000 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | National Centre for Mental Health |
| Amount | £2,000,000 (GBP) |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | Neurodevelopmental Disorders: What happens when children grow up and why? |
| Amount | £893,353 (GBP) |
| Funding ID | 204895/Z/16/ZI |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2021 |
| Description | Neuroimmunology fellowship training program |
| Amount | £347,034 (GBP) |
| Organisation | Sanofi |
| Department | Genzyme Therapeutics Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2020 |
| Description | Neuronal mechanisms of developmental cognitive impairment in the Snord1 16del model for Prader-Willi Syndrome |
| Amount | £3,300 (GBP) |
| Organisation | Prader-Willi Syndrome Association |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2019 |
| Description | Neuroscience Research Fellows Programme |
| Amount | £470,637 (GBP) |
| Organisation | The Jane Hodge Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 08/2020 |
| Description | Novel strategies for cell-based neural reconstruction |
| Amount | £415,000 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2020 |
| End | 12/2023 |
| Description | Pathways to psychosis: Investigating environmental, cognitive and genetic mechanisms underlying development of psychotic experiences in young adults |
| Amount | £1,062,530 (GBP) |
| Funding ID | MR/M006727/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 02/2020 |
| Description | Physical activity and exercise outcomes in Huntington's disease |
| Amount | £411,005 (GBP) |
| Funding ID | Co-applicant |
| Organisation | Gossweiler Foundation |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 07/2017 |
| End | 12/2019 |
| Description | Pilot investigation to characterise the in vitro effects of FAN1 in Huntington's disease |
| Amount | £470,460 (GBP) |
| Organisation | CHDI Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 07/2018 |
| End | 06/2020 |
| Description | Pilot study of motor coordination disorder in 22q11.2 deletion syndrome |
| Amount | £8,935 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 12/2016 |
| Description | Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability |
| Amount | £48,502 (GBP) |
| Organisation | Baily Thomas Charitable Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2020 |
| Description | Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability |
| Amount | £48,502 (GBP) |
| Organisation | Baily Thomas Charitable Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2020 |
| Description | Preterm birth and neuropsychiatric genetic risks: a pilot investigation |
| Amount | £291,744 (GBP) |
| Funding ID | MR/N025288/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2018 |
| Description | Profiling post-translational modifications of histone proteins as a determinant of Parkinson's susceptibility |
| Amount | £232,404 (GBP) |
| Funding ID | G-1502 |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 07/2018 |
| Description | Prognosis following early aggressive disease-modifying therapy in MS |
| Amount | £44,696 (GBP) |
| Funding ID | 49 |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 02/2018 |
| Description | Promoting neural transplantation-induced brain repair by modulating the local immune environment, using an implantable delivery system |
| Amount | £40,000 (GBP) |
| Organisation | Oakgrove Medical Charitable Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2018 |
| Description | Promotion of physical activity in Huntington's Disease clinics |
| Amount | £10,300 (GBP) |
| Funding ID | Co-applicant |
| Organisation | Huntington's Disease Association England & Wales (HDA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 03/2019 |
| Description | Rapid detection and characterisation of life-threatening neurological infections |
| Amount | £24,161 (GBP) |
| Funding ID | Co-applicant |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 08/2017 |
| Description | Rapid detection of life threatening neurological infection by detecting immune fingerprints in cerebrospinal fluid |
| Amount | £49,996 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2020 |
| Description | Real-time MRI neurofeedback market evaluation |
| Amount | £10,258 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 12/2016 |
| Description | Real-time functional magnetic resonance imaging neurofeedback for functional motor recovery after stroke |
| Amount | £54,194 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 12/2016 |
| Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
| Amount | £310,234 (GBP) |
| Funding ID | 209176 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2022 |
| Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
| Amount | £310,234 (GBP) |
| Funding ID | 209176 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2022 |
| Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
| Amount | £310,234 (GBP) |
| Funding ID | Judith Allardyce |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2021 |
| Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
| Amount | £310,234 (GBP) |
| Funding ID | 209176 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2022 |
| Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
| Amount | £310,234 (GBP) |
| Funding ID | Judith Allardyce |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2021 |
| Description | Studentship |
| Amount | £5,000 (GBP) |
| Organisation | Hashemite University |
| Sector | Academic/University |
| Country | Jordan |
| Start | 10/2018 |
| End | 09/2019 |
| Description | TG1101-RMS302 Phase III: UbLiTuximab in Multiple Sclerosis treatment effects (ULTIMATE II STUDY) |
| Amount | £5,527 (GBP) |
| Organisation | Cardiff and Vale University Health Board |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2021 |
| Description | TRial designs for DElivery of Novel Therapies for Neurodegeneration (TRIDENT) |
| Amount | £184,128 (GBP) |
| Funding ID | RfPPB-16a-1298 |
| Organisation | Health and Care Research Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2019 |
| Description | Targeting ERK signalling to emeliorate intellectual disability and autism spectrum disorder associated with chromosomal rearrangements at 16p11.2 |
| Amount | £196,566 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2023 |
| Description | Targeting ERK signalling to emeliorate intellectual disability and autism spectrum disorder associated with chromosomal rearrangements at 16p11.2 |
| Amount | £1,329,545 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2023 |
| Description | The Hodge Centre for Neuropsychiatric Immunology |
| Amount | £1,021,169 (GBP) |
| Funding ID | Co-applicant |
| Organisation | The Jane Hodge Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2022 |
| Description | The Hodge Centre for Neuropsychiatric Immunology |
| Amount | £1,021,169 (GBP) |
| Organisation | The Jane Hodge Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2022 |
| Description | The UK7T network: Developing the ultra-high field MRI platform for biomedical research |
| Amount | £180,843 (GBP) |
| Funding ID | MR/N008537/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2018 |
| Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects |
| Amount | £288,555 (GBP) |
| Funding ID | 104210 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimers disease |
| Amount | £298,040 (GBP) |
| Funding ID | 2018/20180222 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | The genomic basis of human induced pluripotent stem (iPS) cell differentiation into eye-like tissues |
| Amount | £610,953 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 12/2022 |
| Description | The impact of rare variants affecting GABA and glutamate gene sets in schizophrenia: An MEG study |
| Amount | £44,206 (GBP) |
| Organisation | Brain & Behaviour Research Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 01/2016 |
| End | 01/2019 |
| Description | The phenotypic expression of autism spectrum disorder in adults |
| Amount | £29,984 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 01/2019 |
| Description | The phenotypic expression of neuropsychiatric copy number variants |
| Amount | £193,209 (GBP) |
| Funding ID | Kim Kendall |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2020 |
| Description | The phenotypic expression of neuropsychiatric copy number variants |
| Amount | £193,209 (GBP) |
| Funding ID | Kim Kendall |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 01/2020 |
| Description | The role of the HMGB1 alarmin in oligodenrogliogenesis and white matter repair |
| Amount | £5,000 (GBP) |
| Organisation | Royal College of Surgeons of England |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 07/2020 |
| Description | Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease |
| Amount | £136,502 (GBP) |
| Funding ID | MR/P007651/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2018 |
| Description | To develop, design, promote and evaluate an online community portal and app |
| Amount | £30,000 (GBP) |
| Organisation | Big Lottery Fund |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 10/2018 |
| Description | To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia |
| Amount | £2,960,749 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia |
| Amount | £2,960,749 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia |
| Amount | £2,960,749 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia |
| Amount | £2,960,749 (GBP) |
| Organisation | Takeda Pharmaceutical Company |
| Sector | Private |
| Country | Japan |
| Start | 10/2018 |
| End | 09/2022 |
| Description | To support families of children with brain disorders by exploiting an embedding new knowledge and capabilities to develop highly innovative solutions and collaborative partnership that bring lasting improvements to the lives of thousands of children |
| Amount | £274,115 (GBP) |
| Organisation | Cerebra |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2022 |
| Description | Tracking Parkinson's - the long term development and analysis of the Parkinson's repository of biomarkers and networked datasets |
| Amount | £125,535 (GBP) |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2016 |
| End | 11/2020 |
| Description | Training on advanced stem cell technologies in neurology |
| Amount | £484,652 (GBP) |
| Funding ID | 813851 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2018 |
| End | 12/2023 |
| Description | Treading Anxiety to PreEnt Relapse in Schizophrenia (TAPERS) - a feasibility trial |
| Amount | £174,314 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2020 |
| Description | UK DRI at Cardiff |
| Amount | £710,042 (GBP) |
| Organisation | UK Dementia Research Institute |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2022 |
| Description | Ultra-high field MRI: Advancing clinical neuroscientific research in experimental medicine. |
| Amount | £6,700,929 (GBP) |
| Funding ID | MR/M008932/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2016 |
| Description | Understanding the role of DNA repair in Huntington's disease pathogenesis: towards novel therapeutic target |
| Amount | £304,780 (GBP) |
| Funding ID | MR/P001629/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 07/2019 |
| Description | Using shape memory scaffolds to increase transplant survival and prepare a nigro/stiratal "bridge" |
| Amount | £28,839 (GBP) |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 10/2017 |
| Description | Using the smartphone to monitor mood states |
| Amount | £45,775 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 11/2016 |
| Description | Utilising adoption-based research designs to examine the interplay between family relationship processes and child developmental outcomes |
| Amount | £199,868 (GBP) |
| Funding ID | ES/L014718/1 |
| Organisation | Economic and Social Research Council |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 01/2017 |
| Description | Validating prognostic biomarkers for colorectal cancer and determining their clinical utility |
| Amount | £155,801 (GBP) |
| Organisation | Cancer Research Wales |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2021 |
| Title | AD Genetics Scotland |
| Description | Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff. |
| Type Of Material | Biological samples |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Ongoing collection of samples, no publications to date. |
| Title | BAC cell lines |
| Description | Bacterial method to insert gene mutations of interest into cell lines |
| Type Of Material | Cell line |
| Provided To Others? | No |
| Impact | none yet |
| Title | Brain Bank - Alzheimers |
| Description | We have recently created a brain bank based upon the longitudinal sample, to provide the wider research community with multiple tissue samples on well characterised individuals. |
| Type Of Material | Biological samples |
| Year Produced | 2007 |
| Provided To Others? | Yes |
| Impact | Multiple publications and media coverage |
| Title | Brains for Dementia Research |
| Description | Brains; cases and controls |
| Type Of Material | Biological samples |
| Year Produced | 2007 |
| Provided To Others? | Yes |
| Impact | unknown |
| Title | CRISPR generated cell lines |
| Description | Cell lines created using genome editing tool |
| Type Of Material | Cell line |
| Provided To Others? | No |
| Impact | none yet |
| Title | Calibration |
| Description | Calibration methods development |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | ESRC Research methods festival presentation on cross-cohort comparisons, including calibration. Invited Annual Research Review on time trends in press in Journal of Child Psychology and Psychiatry. |
| URL | http://www.ncrm.ac.uk/RMF2014/home.php |
| Title | EOAD cohort |
| Description | We are collecting a biological sample of early onset Alzheimer's disease individuals for research. This includes phenotypic data and biological data and is set to become the largest EOAD biobank in the world. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | This earlier more aggressive form of the disease will be studied in order to shed light on disease mechanisms and prospective therapies. |
| Title | Further developing HiSpot Cultures |
| Description | Further refinement and validation of HiSpot / OrganDot cultures for studying altered hippocampal neurogenesis in human Temporal Lobe Epilepsy |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | Paper in Preparation - further validation work in progress |
| Title | Generated a tm1d constitutive Setd1a knockout mouse model |
| Description | By crossing our Tm1c Setd1a conditional ready knockout model to a CMV-cre (a ubiquitous cre-line) we were able to generate a full (constitutive) Setd1a knockout mouse line free from the targeting construct and markers (such as LacZ) |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2019 |
| Provided To Others? | Yes |
| Impact | None as yet |
| Title | Generation of conditional-ready (Tm1c) Setd1a knockout |
| Description | A conditional-ready (Tm1c) knockout mouse model of the schizophrenia and developmental delay gene, Setd1a |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | This model allows us and other researchers to generate region specific knockouts of this key schizophrenia and developmental delay gene |
| Title | Human Stem Cell Modelling of Brain Disease |
| Description | Cellular models in vitro |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Provided To Others? | No |
| Impact | unknown |
| Title | Novel method for detecting pure and interrupted short tandem repeat sequences in next-generation sequencing data |
| Description | This is an algorithm developed by Sergey (the bioinformaticist who worked on this project) to detect both pure and quasi-short tandem repeats in the genome. Previous algorithms only detect pure short tandem repeats. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | It has enables us to read the sequence of several quasi repeats in our sequencing data which previously were unreadable. |
| Title | POLARIS |
| Description | We developed a novel approach to genetic set-based analysis, which accounts for linkage disequilibrium between SNPs and informs the analysis with previously reported effect sizes of a SNP's association to disease. We call this method POLARIS: POlygenic Linkage disequilibrium-Adjusted RIsk Score. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | the paper is under review, the software tool is available for testing |
| URL | http://github.com/BakerEA/POLARIS |
| Title | Polygenic score |
| Description | With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. |
| Title | Setd1a-nestin-cre knockout |
| Description | A knockout of the schizophrenia and developmental delay gene Setd1a limited to nestin expressing cells only. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Allows behavioural assessment of thisschizophrenia and developmental delay gene |
| Title | 1000 brains |
| Description | I have lead the creation of a research resource (database) of around 1000 brain MRI scans and full genomic data to estimulate and facilitate research into neuroimgaing genetics. We make this database freely available to interested researchers within Cardiff University |
| Type Of Material | Database/Collection of data |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Two papers have been recently published using this resource: PMID: 26048451 doi:10.1038/tp.2015.195. another paper is currently under revision two further research projects are undergoing using data from the '1000 brains'. |
| Title | Alzhemer's Disease Polygenic Risk Profiling |
| Description | This model used data from the powerful dataset comprising 17 008 cases and 37 154 controls obtained from the International Genomics of Alzheimer's Project (IGAP). Alzheimer's disease (AD) Polygenic risk scores were generated for 3177 cases and 7277 controls (GERAD data) and tested whether the alleles identified to associate with disease in IGAP sample are significantly enriched in the cases relative to the controls in the GERAD sample. The disease prediction accuracy was investigated in a sample of 3049 cases and 1554 controls (for whom APOE genotype data was available) by means of sensitivity, specificity, area under the receiver operating characteristic curve (AUC) and positive and negative predictive values. The best prediction accuracy AUC = 78.2% (95% confidence interval 77-80%) was achieved by a logistic regression model with APOE, the polygenic score, sex and age as predictors. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | This approach is used to create SNP arrays for AD prediction (for research only so far). |
| Title | DPUK Genomics portal |
| Description | The DPUK Genetics portal provides a collaborative platform for individuals, DPUK cohorts and the wider research community to share and access research outputs from genetic research. The platform provides two key tools for finding, sharing and analysing genetic data; The Results Registry tool, accessible via the main DPUK web portal, allows searching and uploading of genetic results data. This tool provides a rich set of search tools specific to genetic data and includes visualisation using the popular JBrowse genomic browser. This tool will allow users to share this data. This can be done under secure data transfer agreements if necessary. The second tool is the Genetic Data Browser this is available exclusively within the secure DPUK infrastructure. This will allow users to create cross-cohort comparison studies based on genotypic datasets and linked phenotypic data. This tool provides an interactive dashboard which can pull in phenotypic data and genetic markers from GWAS data and allow users to intuitively explore, combine and export patient cohorts. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The DPUK Genetics portal, housed on the DPUK platform, allows non bioinformatic-expert users to explore components of genetic data within a secure environment. We have provided access to an international consortium, GERAD, via the DPUK data portal. This is a dataset of over 18,000 cases and controls (detailed in Table 2), as well as over 5,600 samples to date submitted to the EADB, the European AD DNA bank for deciphering the missing heritability of Alzheimer's disease |
| URL | https://portal.dementiasplatform.uk/ |
| Title | GERAD Exome chip data |
| Description | Dataset from Illumina Exome chip platform (version 1.0 and v1.1), approximately 6,000 cases and 4,000 controls |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | papers in press |
| Title | GERAD GWAS |
| Description | Genome-wide association study data of over 3,000 AD cases and 7,000 controls |
| Type Of Material | Database/Collection of data |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | multiple publications |
| Title | IGAP dataset |
| Description | Mega-meta analysis data of over 17,000 AD cases and 30,000 controls |
| Type Of Material | Database/Collection of data |
| Year Produced | 2013 |
| Provided To Others? | Yes |
| Impact | Lambert et al. 2013 (PMID:24162737), Escott-Price et al. 2014(in press), Farrer et al. 2014 (submitted) |
| Title | Identifying CNVs in the UK Biobank |
| Description | I am caling all CNVs in the 502,000 people from the UK Biobank. These will be made avaialble to the Biobank, for use by researchers from all over the world. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | This is still on-going and the data have not been uploaded yet (probably late 2016. |
| Title | PGC Pathways |
| Description | Combining results of several pathway methods on PGC GWAS data |
| Type Of Material | Data analysis technique |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Publication |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/25599223 |
| Title | Schizophrenia GWAS meta-analysis results |
| Description | Full genome results of our recent Nature Genetics paper CLOZUK schizophrenia GWAS meta-analysis |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | has only been active since publication 1 week ago |
| URL | http://walters.psycm.cf.ac.uk |
| Title | Summary statistics for expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders |
| Description | This dataset contains summary statistics for eQTL (Expression Quantitative Trait Loci) analyses using 120 human fetal brains from the second trimester of gestation (12 to 19 post-conception weeks). Expression matrices, covariates, and summary statistics are provided for all tested eQTL and for top eQTL for all genes and transcripts. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | As of 12th Feb 2019, the data have been downloaded 135 times in the 2.5 months that they have been available. |
| URL | https://doi.org/10.6084/m9.figshare.6881825 |
| Description | ADHD genetics |
| Organisation | Psychiatric GWAS Consortium (PGC) |
| Department | ADHD Sub Group |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | joint papers, samples |
| Collaborator Contribution | joint papers |
| Impact | papers published |
| Start Year | 2007 |
| Description | Asterand Biosciences |
| Organisation | Asterand |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developing the culture technology for 3D cultures of Huamn Glioma tumours |
| Collaborator Contribution | Potential to commercialise and develop SOPs |
| Impact | N/A |
| Start Year | 2016 |
| Description | Atmohealth |
| Organisation | FACE Recording & Measurement Systems Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Working with FACE to develop bespoke database solutions for the departments research |
| Collaborator Contribution | developing bespoke database solutions |
| Impact | None to date |
| Start Year | 2016 |
| Description | BLISS -the preterm birth charity |
| Organisation | Bliss |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | WE are working with BLISS as we will do the science and they will conduct focus groups with parents |
| Collaborator Contribution | They will conduct two focus groups |
| Impact | None yet |
| Start Year | 2017 |
| Description | BRACE |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | advice and training on genomic data analysis |
| Collaborator Contribution | Investigating the genetic overlap between AD and other diseases or traits using polygenic risk scores in Avon Longitudinal Study of Parents and Children (ALSPAC) |
| Impact | 1. Application of newly developed methodology (MR-Base), which hallows to do rapid high-throughput analysis of potentially interesting traits and environmental exposures. 2. Test for shared genetic susceptibility between AD and early life lipid levels, glycaemic, anthropometric, behavioral and cognitive traits in ALSPAC children |
| Start Year | 2016 |
| Description | Biomarkers for psychosis - RCSI |
| Organisation | Royal College of Surgeons in Ireland |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Co-app on grant, obtaining data, co-authoring papers |
| Collaborator Contribution | Led grant application and co-authored/led papers |
| Impact | HBI Research Grants Publications |
| Start Year | 2014 |
| Description | Biopsy tissue from glioma. |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2017 |
| Description | Bipolar - Glasgow |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Grant lead, co-supervising student |
| Collaborator Contribution | n/a |
| Impact | MHRUK studentship and publications |
| Start Year | 2015 |
| Description | Broad Institute collaboration |
| Organisation | Broad Institute |
| Department | Stanley Center for Psychiatric Research |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provided well characterised samples for genotyping. |
| Collaborator Contribution | SNP genotyping and exome sequencing. |
| Impact | none as yet |
| Description | CADR |
| Organisation | Bangor University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | sample preparation, data analysis |
| Collaborator Contribution | data analysis, sample collections |
| Impact | none yet |
| Start Year | 2014 |
| Description | CADR |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | sample preparation, data analysis |
| Collaborator Contribution | data analysis, sample collections |
| Impact | none yet |
| Start Year | 2014 |
| Description | CD59 quantification in MS/NMO/CIS/controls |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data |
| Collaborator Contribution | Provision of biological samples and clinical data |
| Impact | For publications, either published or in process. |
| Start Year | 2016 |
| Description | CFAS |
| Organisation | Bangor University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are working together with CFAS to prepare the 3,000 participant cohort for genetic research. |
| Collaborator Contribution | Provided cohort |
| Impact | CFAS prepared for Genetic analysis |
| Start Year | 2009 |
| Description | CFAS |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are working together with CFAS to prepare the 3,000 participant cohort for genetic research. |
| Collaborator Contribution | Provided cohort |
| Impact | CFAS prepared for Genetic analysis |
| Start Year | 2009 |
| Description | CLOZUK |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This has been a 10 year project leading to the acquisition of the largest sample of those with schizophrenia in the world which has led to over 30 publications and multiple grants investigating the genetic basis of schizophrenia, treatment-resistance, adverse effects of antipsychotic treatment and metabolism of these drugs. |
| Collaborator Contribution | These data have been acquired by Cardiff University but through various projects Leyden Delta and King's partners (Dr James MacCabe) have made important contributions to this work. |
| Impact | Grants and many papers have emerged |
| Start Year | 2011 |
| Description | CLOZUK |
| Organisation | Leyden Delta BV |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | This has been a 10 year project leading to the acquisition of the largest sample of those with schizophrenia in the world which has led to over 30 publications and multiple grants investigating the genetic basis of schizophrenia, treatment-resistance, adverse effects of antipsychotic treatment and metabolism of these drugs. |
| Collaborator Contribution | These data have been acquired by Cardiff University but through various projects Leyden Delta and King's partners (Dr James MacCabe) have made important contributions to this work. |
| Impact | Grants and many papers have emerged |
| Start Year | 2011 |
| Description | CNV in drug-resitant JME |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2015 |
| Description | Cell Therapy for Brain repair |
| Organisation | Cardiff University |
| Department | Brain repair group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Demonstration of the effect of the microenvironment on cell transplants |
| Collaborator Contribution | Expertise in animal models of cell transplantation |
| Impact | Life Sciences Bridging Fund grant |
| Start Year | 2015 |
| Description | Child and Adolescent Research |
| Organisation | University of Sussex |
| Department | School of Psychology Sussex |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | scientific input to design of grant and ongoing papers |
| Collaborator Contribution | scientific input to design of grant and ongoing papers |
| Impact | Multiple papers |
| Start Year | 2013 |
| Description | Collaboration with Bristol MRC Unit |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Joint work on ADHD and risk alleles |
| Collaborator Contribution | ALSPAC data and science |
| Impact | Multiple papers and ongoing collaboration |
| Start Year | 2009 |
| Description | Collaboration with Eisai AiM Institute |
| Organisation | Eisai Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Consultancy on Polygenic risk score for clinical trials |
| Collaborator Contribution | We are in the process of negotiations |
| Impact | potentially this collaboration will pay for a time of a postdoctoral researcher |
| Start Year | 2018 |
| Description | Collaboration with NIMH |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Mental Health (NIMH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Joint paper on genetic architecture of irritability. |
| Collaborator Contribution | We jointly have written a paper on findings to do with the genetic architecture of irritability |
| Impact | Paper submitted for publication |
| Start Year | 2016 |
| Description | Collaboration with the University of Wuerzburg |
| Organisation | University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | We are using my expertise in CNV and sequencing analysis and the German team are contributing their 2000 patients/controls DNA samples |
| Collaborator Contribution | The team in Wuerzburg has collected one of the largest and best-characterised datasets of schizophrenia patients. They are happy to collaborate with us, due to my long-term involvement with their research. We will probably genotype and sequence their samples. |
| Impact | CNV analsyis of de novos: this will make part of a large paper under preparation. |
| Start Year | 2010 |
| Description | Complement System in MS |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process |
| Start Year | 2015 |
| Description | Complement biomarkers in epilepsy |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2016 |
| Description | DNA genome screening, Illumina |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2016 |
| Description | DPUK |
| Organisation | Medical Research Council (MRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Steering Group member, DPUK work package lead. |
| Collaborator Contribution | Creating Dementia Platform UK Data Portal |
| Impact | In the process of creating on-line database with dementia cohorts, available in the UK and pipelines for data analyses. Multidisceplinary: genetics, bioinfirmatics, IT. |
| Start Year | 2014 |
| Description | DartingtonSRUresilience |
| Organisation | Social Research Unit at Dartington |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Informed senior research staff and trustees of findings from the project |
| Collaborator Contribution | Hosted seminar, and agreed to assist in preparation of policy brief and dissemination of findings to local and national stakeholders |
| Impact | Dartington Social Research Unit hosted seminar to discuss findings |
| Start Year | 2015 |
| Description | De novo mutations in schizophrenia patients |
| Organisation | University of Wurzburg |
| Department | Department of Psychiatry, Psychosomatics and Psychotherapy |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | A scholar from Germany spent 2 years working in our department. We have worked on genotyping thier collection of 400 families |
| Collaborator Contribution | They provided the DNA samples, part of the funding, work and expertise |
| Impact | An article is being drafted. |
| Start Year | 2011 |
| Description | Disentangling the population- versus treatment-specific effect on the milder disease course observed during Interferon beta treatment in patients with Multiple Sclerosis |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | This is a collaboration aimed at disentanginge the population- versus treatment-specific effect on the disease course during IFN beta treatment in patients with MS by testing, in two cohorts belonging to different geographical areas of MS risk (UK and Italy), the impact of demographic and clinical variables that, at the time of treatment commencement, can affect the disease course on treatment and thus can confound the interpretation of treatment influence on clinical outcomes. We will contribute with anonymised patients' data and clinical expertise. |
| Collaborator Contribution | Our collaborators will contribute with with anonymised patients' data and statistical expertise. |
| Impact | No outputs yet. |
| Start Year | 2015 |
| Description | ENIGMA |
| Organisation | National Center for Biotechnology Information (NCBI) |
| Country | United States |
| Sector | Public |
| PI Contribution | We share and contribute data across different research centres around the world to enhance our statisitical power |
| Collaborator Contribution | We are involved in several projects within ENIGMA: Investigating neuroanatomical biomarkers of Bipolar Disorder. Investigating neuroanatomical abnormalities in psychiatric patients and unaffected relatives. Investigating common genetic variances associated to neuroanatomy. |
| Impact | Two papers have so far resulted from this collaboration: doi: 10.1038/mp.2015.227 doi: 10.1007/s11682-013-9269-5 and several contributions to scientific meetings |
| Start Year | 2014 |
| Description | EPAD |
| Organisation | GlaxoSmithKline (GSK) |
| Department | Epidemiology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | GENOTYPING AND ANALYSIS |
| Collaborator Contribution | cohorts, biomarker studies, epidemiological studies, random control studies |
| Impact | none yet |
| Start Year | 2014 |
| Description | Early adversity |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Hosted visit and organised seminar; Joint symposium for NCDS@60 |
| Collaborator Contribution | Coding of prospectively assessed ACEs in National Child Development Study; Joint symposium for NCDS@60 |
| Impact | The long term psychological and physiological consequences of childhood adversities: identifying exposures and pathways over the life course using the NCDS. Paper symposium to be presented at "NCDS 60 years of our lives". London, 2018 |
| Start Year | 2017 |
| Description | Eisai Collaboration |
| Organisation | Eisai Ltd |
| Country | Japan |
| Sector | Private |
| PI Contribution | We are identifying important genes and pathways involved in Alzheimer's disease for further investigation in functional experiments and drug-based tests. |
| Collaborator Contribution | Expertise in functional biology |
| Impact | None yet |
| Start Year | 2015 |
| Description | EpiPGX - biomarkers in epilepsy |
| Organisation | University of Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2016 |
| Description | Eurostemcells |
| Organisation | EU-T0 |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | Eurostemcells is an educational Consortium to provide reliable information about stem cells and their application including their impact on society. My/my team contribute articles, edit reports and information leaflets. |
| Collaborator Contribution | Coordinated by University of Edinburgh. |
| Impact | Information and reports |
| Start Year | 2014 |
| Description | Foundation for Prader-Willi Research "Pre-Clinical Animal Network" (FPWR-PCAN) |
| Organisation | Foundation for Prader-Willi Research (FPWR) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Our expertise has been used to shape the decision making with regards to animal models to be generated and the phenotyping pipeline. |
| Collaborator Contribution | FPWR facilitated the formation and meetings of the FPWR-PCAN and drove the decision-making MRC Harwell, IIT & INMED helped shape the decision making with regards to animal models to be generated and the phenotyping pipeline |
| Impact | Generation of new PWS mouse models by MRC Harwell - these are underway currently |
| Start Year | 2016 |
| Description | Foundation for Prader-Willi Research "Pre-Clinical Animal Network" (FPWR-PCAN) |
| Organisation | Italian Institute of Technology (Istituto Italiano di Tecnologia IIT) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Our expertise has been used to shape the decision making with regards to animal models to be generated and the phenotyping pipeline. |
| Collaborator Contribution | FPWR facilitated the formation and meetings of the FPWR-PCAN and drove the decision-making MRC Harwell, IIT & INMED helped shape the decision making with regards to animal models to be generated and the phenotyping pipeline |
| Impact | Generation of new PWS mouse models by MRC Harwell - these are underway currently |
| Start Year | 2016 |
| Description | Foundation for Prader-Willi Research "Pre-Clinical Animal Network" (FPWR-PCAN) |
| Organisation | MRC Harwell |
| Department | MRC Mammalian Genetics Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our expertise has been used to shape the decision making with regards to animal models to be generated and the phenotyping pipeline. |
| Collaborator Contribution | FPWR facilitated the formation and meetings of the FPWR-PCAN and drove the decision-making MRC Harwell, IIT & INMED helped shape the decision making with regards to animal models to be generated and the phenotyping pipeline |
| Impact | Generation of new PWS mouse models by MRC Harwell - these are underway currently |
| Start Year | 2016 |
| Description | GENAROAD |
| Organisation | Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | data and analyses |
| Collaborator Contribution | data analysis |
| Impact | none yet, paper being prepared for publication |
| Start Year | 2013 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Albert Ludwig University of Freiburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Brigham Young University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Central Institute for Mental Health |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Free University of Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Friedrich-Alexander University Erlangen-Nuremberg |
| Department | Department of Psychiatry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | German Centre for Neurodegenerative Diseases |
| Country | Germany |
| Sector | Public |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Goethe University Frankfurt |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Helmholtz Association of German Research Centres |
| Department | Helmholtz Zentrum Munchen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | King's College London |
| Department | Institute of Psychiatry, Psychology & Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Department | Department of Neurology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Mayo Foundation for Medical Education and Research (MFMER) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Centre for Neuropsychiatric Genetics and Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | National Institutes of Health (NIH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Queen's University Belfast |
| Department | Aging group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University College London |
| Department | Institute of Neurology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University College London |
| Department | MRC Prion Unit and the Dementia Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University Duisburg-Essen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Bonn |
| Department | Department of Psychiatry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Bristol |
| Department | Dementia Research Group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Cambridge |
| Department | Cambridge Institute of Public Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Hamburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Manchester |
| Department | Neuroscience Research Institute (NRI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Nottingham |
| Department | Centre for Genetics and Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Southampton |
| Department | Clinical and Experimental Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Zurich |
| Department | Functional Genomics Centre Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Washington University in St Louis |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Autonomous University of Madrid |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Brigham Young University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Cardiff University |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Fondazione Santa Lucia |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Hospital de Sant Pau |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Neuroscience; IOP |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Queen's University Belfast |
| Department | Aging group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | Saarland University |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University College London |
| Department | MRC Prion Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Bonn |
| Department | Department of Psychiatry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Cantabria |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Navarra |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Nottingham |
| Department | Centre for Genetics and Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Oviedo |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Southampton |
| Department | Clinical and Experimental Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GERAD Exome Chip Consortium |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design |
| Collaborator Contribution | DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation |
| Impact | Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters). |
| Start Year | 2012 |
| Description | GW Pharmaceuticals |
| Organisation | GW Pharmaceuticals |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Using data acquired under previous grants to guide research into potential therapeutics |
| Collaborator Contribution | Providing therapeutics (subject to confidentiality agreement) for testing |
| Impact | Research contract funding |
| Start Year | 2015 |
| Description | GW4 epigenetics consortium |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Collaborator Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Impact | Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund |
| Start Year | 2014 |
| Description | GW4 epigenetics consortium |
| Organisation | University of Bath |
| Department | Department of Biology and Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Collaborator Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Impact | Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund |
| Start Year | 2014 |
| Description | GW4 epigenetics consortium |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Collaborator Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Impact | Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund |
| Start Year | 2014 |
| Description | GW4 epigenetics consortium |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Collaborator Contribution | Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund |
| Impact | Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund |
| Start Year | 2014 |
| Description | GW4 fellowship |
| Organisation | Cardiff University |
| Department | Brain Research Imaging Centre (CUBRIC) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | co-supervisor; advice and training on genomic data analysis |
| Collaborator Contribution | A researcher, Judith Harrison |
| Impact | To explore disease pathways in Alzheimer's disease using MRI Biomarkers and Polygenic Scores |
| Start Year | 2017 |
| Description | Gene expression in Huntington's disease |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Analysis of gene expression data. |
| Collaborator Contribution | generation of gene expression data |
| Impact | 10.1093/hmg/ddw142, 10.1038/srep44849 . multidisciplinary - biostatistics/bioinformatics/molecular biology |
| Start Year | 2013 |
| Description | Genetic Modifiers in Huntington's disease |
| Organisation | Massachusetts General Hospital |
| Department | Centre for Human Genetic Research |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | I am the European lead of the Genetic Modifiers in Huntington's disease (GeM-HD) collaboration. They pay for an analyst in my research group. |
| Collaborator Contribution | The partners conduct the genotyping for this project and also perform some analysis. |
| Impact | Keum, J.et al. 2016. The HTT CAG expansion mutation determines age at death but not disease duration in Huntington's Disease. American Journal of Human Genetics 98(2), pp. 287-298. pdf Lee, J.et al. 2015. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162(3), pp. 516-26. (10.1016/j.cell.2015.07.003) Correia, K.et al. 2015. The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. Journal of Huntington's Disease 4(3), pp. 279-284. (10.3233/JHD-150169) . http://dx.doi.org/10.1093/hmg/ddx286; doi: 10.1038/ejhg.2017. |
| Start Year | 2010 |
| Description | Genetics of trinucleotide repeat disorders |
| Organisation | University College London |
| Department | Institute of Neurology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I led a collaboration investigating whether the genetic modifiers of Huntington's disease also acted as modifiers in other repeat disorders |
| Collaborator Contribution | DNA from subjects with trinucleotide repeat disorders, genotyping. |
| Impact | Jones, L., Houlden, H. and Tabrizi, S. J. 2017. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology 16(1), pp. 88-96. (10.1016/S1474-4422(16)30350-7) pdf Bettencourt, C.et al. 2016. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Annals of Neurology 79(6), pp. 983-990. (10.1002/ana.24656) pdf |
| Start Year | 2015 |
| Description | Genomics England |
| Organisation | Genomics England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We are in the very early stages of discussion with Genomics England, but we hope to be able to use their facilities for whole Genome sequencing. This will mean that we generate valuable data on the largest EOAD cohort world-wide. |
| Collaborator Contribution | Genomics England have the equipment and infrastructure set up for the very expensive and technical whole exome sequencing. |
| Impact | None yet |
| Start Year | 2015 |
| Description | GlaxoSmithKline Cardiff Collaboration |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Prof Williams made contact with a GSK rep at the Global Genetics Congress in Baltimore, September 2016. GSK were extremely interested in collaborating with the Cardiff team. Specifically, GSK have an interest in the latest confidential experimental results and translating these from genetic to biological meaning. This will speed up the Cardiff Team's discovery of potential molecular targets for personalised disease treatment. Cardiff will contribute expertise in Alzheimer's disease genetics. |
| Collaborator Contribution | GSK will contribute their expertise in disease models and drug mechanisms. |
| Impact | This collaboration has been brought under a confidentiality agreement. Parties involved are experts in genetics and functional biology. |
| Start Year | 2016 |
| Description | Graves disease, alemtuzamab patients |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2015 |
| Description | HCRW Brain Repair and Intracranial Neurotherapeutics (B.R.A.I.N.) Unit |
| Organisation | Health and Care Research Wales |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Director of BRAIN Unit |
| Collaborator Contribution | Supported Bionbanking, R&D regulation, Technician support for Human tissue Biobanking, Suport of Clinical Research Fellow for consent and Tissue Collection |
| Impact | Research just commenced. |
| Start Year | 2016 |
| Description | HD modifiers |
| Organisation | CHDI Foundation |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Analysis of genome-wide HD data |
| Collaborator Contribution | Provision of data, paying salary of researcher |
| Impact | Analysis of genome-wide HD data |
| Start Year | 2015 |
| Description | Identifying the pathogenic triggers of CD8 T-cels in MS |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2015 |
| Description | Informed Consent for DMTs in MS |
| Organisation | International Multicentre persistent ADHD CollaboraTion (IMpACT) |
| Country | Global |
| Sector | Academic/University |
| PI Contribution | I am contributing to write information sheets and informed consents for DMTs in MS. |
| Collaborator Contribution | My collaborators are also contributing to the writing of these information and consents |
| Impact | No outputs yet. |
| Start Year | 2014 |
| Description | Informed consent for disease modifying treatments in MS |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Multicentre collaboration to gain an international consensus on informed consent for disease modifying treatments in MS. I contributed to the project by drafting consent forms for patients and by participating to workshops and discussions of the group. |
| Collaborator Contribution | Intellectual contribution and medico-legal revision of the documents. |
| Impact | This is a multidisciplinary collaboration. The consensus group has drafted informed consents for the licensed disease modifying treatments in MS. |
| Start Year | 2014 |
| Description | Innovate UK |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Consultancy |
| Collaborator Contribution | Design of Alzhemer's disease chip |
| Impact | In the process of designing of Alzhemer's disease SNP array. Multidisceplinary: medical genetics, bioinformatics, statistics |
| Start Year | 2015 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | Boston University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | Genetic and Environmental Risk in Alzheimer's Disease (GERAD) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | University of Lille |
| Country | France |
| Sector | Academic/University |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Genomics of Alzheimer's Project (IGAP) |
| Organisation | University of Pennsylvania |
| Department | Alzheimer's Disease Genetics Consortium (ADGC) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis |
| Impact | papers in progress |
| Start Year | 2012 |
| Description | International Multiple Sclerosis Genetics Consortium |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | Provision of DNA from an established patient cohort. |
| Collaborator Contribution | Genomic analysis |
| Impact | Numerous publications |
| Start Year | 2014 |
| Description | International Multiple Sclerosis Genetics Consortium |
| Organisation | University of California, San Francisco |
| Department | School of Medicine (UCSF) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provision of DNA from an established patient cohort. |
| Collaborator Contribution | Genomic analysis |
| Impact | Numerous publications |
| Start Year | 2014 |
| Description | International Multiple Sclerosis Genetics Consortium |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of DNA from an established patient cohort. |
| Collaborator Contribution | Genomic analysis |
| Impact | Numerous publications |
| Start Year | 2014 |
| Description | JPND PERADES |
| Organisation | JPND Research |
| Country | Global |
| Sector | Academic/University |
| PI Contribution | Coordinator of the EU Joint Programme - Neurodegenerative Disease Research PERADES project |
| Collaborator Contribution | Containing researchers from 11 countries. Exploiting new statistical approaches to genetic data, researchers will calculate polygenic risk scores and use these to identify individuals at both high and low risk of developing Alzheimer's disease. |
| Impact | The JPND project brings together researchers across Europe to perform vast replication studies of variants of interest in Alzheimer's disease. The project is also the first to begin exome sequencing of the EOAD cohort, which we hope will shed light on the early stages of disease. Importantly, this project brings together the areas of genetics, a variety of omics, polygenic scores, and population studies in a powerful combination to further our knowledge of Alzheimer's disease. |
| Start Year | 2013 |
| Description | Jackson labs collaboration |
| Organisation | The Jackson Laboratory |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | We provide the most up to date genetic human Alzheimer's disease study results and interpretation. |
| Collaborator Contribution | Jackson labs provide their expertise in translation of human study findings into small animal transgenic models of genetic diseases. |
| Impact | Attempts so far to tie down both a project plan and committed funding, have not been successful. We are currently exploring alternative methods to whole animal experiments. We hope that in the future we will be able to regenerate interest in this promising collaboration. |
| Start Year | 2016 |
| Description | MRC AD Cohort |
| Organisation | King's College London |
| Department | Institute of Psychiatry, Psychology & Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Centre for Developmental Neurobiology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | University of Cambridge |
| Department | Department of Medical Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | University of Cambridge |
| Department | Department of Public Health and Primary Care |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC fellowship |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | advice and training on genomic data analysis |
| Collaborator Contribution | A researcher, Dr. Emma Anderson, who is a highly productive junior researcher |
| Impact | 1. To improve causal inference in mendelian randomization studies of dementia 2. To improve understanding of the genetic risk for dementia and trajectories of cognitive capabilities in aging 3. To identify modifiable risk factors that are related to dementia and cognitive decline |
| Start Year | 2016 |
| Description | Measuring complement activation in diagnosis and management of neuromyelitis optica |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2014 |
| Description | Metabolomics study |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2016 |
| Description | NIHR Developing and evaluating an online psychoeducation package for adolescent depression |
| Organisation | National Institute for Health Research |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Advisor on resilience in adolescents at high risk of developing depression. Thapar is supervisor of NIHR Fellowship |
| Collaborator Contribution | Development of evidence-based psychoeducation package for young people with or at high-risk of depression. Elements informed by findings of resilience grant (e.g. role of co-parent when one parent is depressed). Provided input from clinical and psychoeducation perspectives. Now advising on prevention and intervention approaches as part of new Wolfson Centre for Young People's Mental Health |
| Impact | None as yet |
| Start Year | 2013 |
| Description | NIMH fellowship partnerships |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Mental Health (NIMH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Joint research supervision of fellowship |
| Collaborator Contribution | Hosting and cosupervising WT clinical research fellow |
| Impact | None yet-fellow was on maternity leave |
| Start Year | 2015 |
| Description | Neuroscience stem cell PhD collaboration |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Knowledge of stem cell neuroscience and analysis |
| Collaborator Contribution | Knowledge of phenotyping |
| Impact | Ongoing research |
| Start Year | 2014 |
| Description | PGC |
| Organisation | Psychiatric GWAS Consortium (PGC) |
| Country | Global |
| Sector | Academic/University |
| PI Contribution | We contribute to the international Psychiatric Genetics Consortium PGC-data, analysis, initating new papers and helping with co-ordination. AThapar was the ADHD representative for the Cross Disorders Group for 2 years. We remain active contributors to the PGC ADHD group |
| Collaborator Contribution | PGC involves the largest world wide psychiatric genetics collaboration and data set. This allows us access to the data set for hypothesis generation |
| Impact | Research papers as recorded under publications. PhD studentship data. |
| Start Year | 2008 |
| Description | PGC |
| Organisation | Psychiatric GWAS Consortium (PGC) |
| Country | Global |
| Sector | Academic/University |
| PI Contribution | We contribute to the international Psychiatric Genetics Consortium PGC-data, analysis, initating new papers and helping with co-ordination. AThapar was the ADHD representative for the Cross Disorders Group for 2 years. We remain active contributors to the PGC ADHD group |
| Collaborator Contribution | PGC involves the largest world wide psychiatric genetics collaboration and data set. This allows us access to the data set for hypothesis generation |
| Impact | Research papers as recorded under publications. PhD studentship data. |
| Start Year | 2008 |
| Description | PTSD and psychosis - Lancaster |
| Organisation | Lancaster University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Preparation of grant application |
| Collaborator Contribution | n/a |
| Impact | Grant application |
| Start Year | 2015 |
| Description | PTSD and psychosis - Liverpool |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Preparation of grant application (Bentall) Publications (Gage) |
| Collaborator Contribution | Co-authored and led publications Led grant application |
| Impact | Publications |
| Start Year | 2015 |
| Description | PTSD and psychosis - Manchester |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Preparation of grant application |
| Collaborator Contribution | Leading grant application |
| Impact | Grant application |
| Start Year | 2015 |
| Description | Pilot study, exosomes in MS plasma |
| Organisation | Cardiff Metropolitan University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and clinical data. |
| Collaborator Contribution | Provision of biochemical and genomic analysis. |
| Impact | For publications, either published or in process. |
| Start Year | 2017 |
| Description | Psychiatric Genetics Consortium |
| Organisation | Psychiatric Genomics Consortium (PGC) |
| Country | Global |
| Sector | Learned Society |
| PI Contribution | I am a PI in the PGC and lead the PGC Cognition in Schizophrenia sub-group as well as lead the treatment-resistant schizophrenia analytic group |
| Collaborator Contribution | This is an international collaboration of hundreds of investigators. Within the cognition group we have been joined by 8 other groups and 12 investigators. In the treatment-resistant schizophrenia group there are another 14 investigators |
| Impact | Biological insights from 108 schizophrenia-associated genetic loci Schizophrenia Working Group of the Psychiatric Genomics Consortium Nature 511 (7510), 421-427 |
| Start Year | 2015 |
| Description | Psychosis epidemiology - Mt Sinai |
| Organisation | Mount Sinai Hospital (USA) |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Preparation & submission of grant applications |
| Collaborator Contribution | Grant funding |
| Impact | Publications Research Grant |
| Start Year | 2015 |
| Description | Psychosis epidemiology - RCSI |
| Organisation | Royal College of Surgeons in Ireland |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Grant lead, analysis of data, writing papers |
| Collaborator Contribution | n/a |
| Impact | MRC & HBRI Research Grants, publications |
| Start Year | 2010 |
| Description | Recruitment of psychiatric patients in Bulgaria |
| Organisation | Medical University of Sofia |
| Department | Psychiatry |
| Country | Bulgaria |
| Sector | Academic/University |
| PI Contribution | I provide research expertise, supervise the project and enter the data into a database. |
| Collaborator Contribution | The collaborators recruit and rate the participants |
| Impact | none yet |
| Start Year | 2012 |
| Description | Renishaw - testing of CED device for Cell delivery |
| Organisation | Renishaw PLC |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Intellectual property supporting cell therapy delivery Model generation Device Testing |
| Collaborator Contribution | Supply of research grade devices Knowledge on in-vitro gel testing |
| Impact | papers in preparation |
| Start Year | 2016 |
| Description | Repeat analysis in next generation sequencing data |
| Organisation | National Institute for Health Research |
| Department | UCLH/UCL Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Analysis of next generation sequencing data |
| Collaborator Contribution | provision of next generation sequencing data from subjects with dementias |
| Impact | ARUK pilot funding award ARUK-PPG2018A-015 |
| Start Year | 2017 |
| Description | Repeat analysis in next generation sequencing data |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Neurological Disorders and Stroke (NINDS) |
| Country | United States |
| Sector | Public |
| PI Contribution | Analysis of next generation sequencing data |
| Collaborator Contribution | provision of next generation sequencing data from subjects with dementias |
| Impact | ARUK pilot funding award ARUK-PPG2018A-015 |
| Start Year | 2017 |
| Description | Rutter text book |
| Organisation | National Institutes of Health (NIH) |
| Department | National Institute of Mental Health (NIMH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Lead editor of the Rutter text book |
| Collaborator Contribution | co lead editor of the Rutter text book |
| Impact | The Rutter text book was published in 2015 |
| Start Year | 2012 |
| Description | STRATA |
| Organisation | University of Sao Paulo |
| Department | Institute of Psychiatry |
| Country | Brazil |
| Sector | Academic/University |
| PI Contribution | work stream lead for multisite MRC stratified medicine study |
| Collaborator Contribution | they have led on project |
| Impact | grant started Oct 2014 |
| Start Year | 2013 |
| Description | SerCymru Fellowship |
| Organisation | Government of Wales |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Supervising a Research Fellow. Project title: Deconvoluting the dementia phenotype using functional genomics and computational approaches |
| Collaborator Contribution | Funding the project |
| Impact | This is a multidisciplinary collaboration between biological sciences and informatics/statistic. We have gained assess to EBI data resources which will be analyzed within the scope of the project. |
| Start Year | 2017 |
| Description | Somatic expansion of simple repeats |
| Organisation | University of Glasgow |
| Department | Institute of Molecular Cell and Systems Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Identifying subjects with specific variants for analysis using methods available in Glasgow |
| Collaborator Contribution | Analysis of repeat lengths using next generation sequencing technology |
| Impact | none yet multidisciplinary, bioinformatics, statstics, molecular biology, genetics |
| Start Year | 2017 |
| Description | Synaptic signalling in neuropsychiatric disorders |
| Organisation | University of Edinburgh |
| Department | Centre for Clinical Brain Sciences (CCBS) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Test whether novel sets of genes relevant to synaptic function (e.g. synaptic signalling complexes characterised via proteomics) are enriched for genetic variants associated with neuropsychiatric disorders. |
| Collaborator Contribution | Access to unpublished molecular neuroscience data (e.g. proteomic data for complexes derived from TAP-tagged synaptic proteins). |
| Impact | Multi-disciplinary: molecular neuroscience, psychiatric genetics PMID: 22083728 |
| Start Year | 2010 |
| Description | Tabrizi |
| Organisation | University College London |
| Department | Institute of Neurology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Statistical pathway analysis of RNA-seq data in HD patients |
| Collaborator Contribution | Data to test analysis methods |
| Impact | No outcomes yet. |
| Start Year | 2015 |
| Description | Takeda |
| Organisation | Takeda Pharmaceutical Company |
| Country | Japan |
| Sector | Private |
| PI Contribution | This collaboration aims to identify new drug targets from genomic data generated by our research groups. |
| Collaborator Contribution | Funding |
| Impact | none as yet |
| Start Year | 2019 |
| Description | The DNA damage response in Huntington's disease |
| Organisation | University of Cambridge |
| Department | Gurdon Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Generation of an assay for repeat analysis in cells and mice. |
| Collaborator Contribution | Expertise and compounds to probe the DDR. Generation of gene-edited mice for crossing with Huntington's model mice. |
| Impact | No outputs yet. |
| Start Year | 2015 |
| Description | UK Biobank neurodenerative disease platform |
| Organisation | King's College London |
| Department | NIHR Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Named investigator on grant application |
| Collaborator Contribution | co-investigators on grant application |
| Impact | Grant application currently under review |
| Start Year | 2013 |
| Description | UK Biobank neurodenerative disease platform |
| Organisation | University College London |
| Department | Dementia Research Centre (DRC) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Named investigator on grant application |
| Collaborator Contribution | co-investigators on grant application |
| Impact | Grant application currently under review |
| Start Year | 2013 |
| Description | UK Biobank neurodenerative disease platform |
| Organisation | University College London |
| Department | Institute of Neurology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Named investigator on grant application |
| Collaborator Contribution | co-investigators on grant application |
| Impact | Grant application currently under review |
| Start Year | 2013 |
| Description | UK Biobank neurodenerative disease platform |
| Organisation | University of Oxford |
| Department | Department of Physiology, Anatomy and Genetics |
| Country | United Kingdom |
| Sector | |